Acrux Ltd.

STATEN ISLAND, N.Y., July 17, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections, today announced that a new patent has been granted by the United States Patent and Trademark Office (USPTO) on July 16, 2024. This patent relates to ibezapolstat and its use to treat C. difficile Infection (CDI) while reducing the recurrence of the infection, as well as improving the health of the gut microbiome. This is the latest in the series of granted patents and pending patent applications that Acrux has filed to protect its proprietary technologies in the field of antimicrobials. Robert J. DeLuccia, Executive Chairman of Acurx, stated: "This patent is very important and timely as ibezapolstat continues to demonstrate previously unexpected and favorable effects on the gut microbiome while at the same time curing the C. difficile bacterial infection and preventing recurrent infection." He further added: "As we continue to prepare for initiation of our Phase 3 clinical program, we expect this feature of ibezapolstat's selective mechanism of action to be further demonstrated and to be an important competitive advantage over currently available antibiotics by reducing the recurrence of the infection. This could have a dramatically favorable effect on patient outcomes and on reducing downstream healthcare costs." David P. Luci, President & CEO of Acurx stated: "This latest patent is part of our company's pivotal product, ibezapolstat, which is a two-dimensional antibiotic to cure infections clinically comparable to marketed antibiotics while restoring the microbiome and preventing reinfections which is unusually positive for CDI antibiotics." Acurx has previously announced that it had a successful FDA End-of- Phase 2 Meeting and Phase 3 Readiness for ibezapolstat for the Treatment of C. difficile Infection. Agreement with FDA was reached on key elements to move forward with its international Phase 3 clinical trial program. Agreement was also reached with FDA on the complete non-clinical and clinical development plan for filing of a New Drug Application (NDA) for marketing approval. Planning continues to advance ibezapolstat into international Phase 3 clinical trials for treatment of C. difficile Infection (CDI). Acurx is also now preparing to submit requests for guidance to initiate clinical trials in the European Union, the United Kingdom, Japan and Canada. About the Ibezapolstat Phase 2 Clinical Trial The completed multicenter, open-label single-arm segment (Phase 2a) study was followed by a double-blind, randomized, active-controlled, non-inferiority, segment (Phase 2b) at 28 US clinical trial sites which together comprise the Phase 2 clinical trial. (see ). This Phase 2 clinical trial was designed to evaluate the clinical efficacy of ibezapolstat in the treatment of CDI including pharmacokinetics and microbiome changes from baseline and continue to test for anti-recurrence microbiome properties seen in the Phase 2a trial, including the treatment-related changes in alpha diversity and bacterial abundance and effects on bile acid metabolism. Key elements for the two Phase 3, non-inferiority, pivotal trials were confirmed and included agreement on the protocol design, patient population, primary and secondary endpoints, and size of the registration safety database. Based on FDA recommendations, and in anticipation of an EMA Scientific Advice Meeting, the primary efficacy analysis will be performed using a Modified Intent-To-Treat (mITT) population consistent with EMA requirements. This will result in an estimated 450 subjects in the mITT population, randomized in a 1:1 ratio to either ibezapolstat or standard-of-care vancomycin, enrolled into the initial Phase 3 trial. The trial design not only allows determination of ibezapolstat's ability to achieve Clinical Cure of CDI as measured 2 days after 10 days of oral treatment, but also includes assessment of ibezapolstat's potential effect on reduction of CDI recurrence in the target population. In the event non-inferiority of ibezapolstat to vancomycin is demonstrated, further analysis will be conducted to test for superiority. The completed Phase 2a segment of this trial was an open label cohort of up to 20 subjects from study centers in the United States. In this cohort, 10 patients with diarrhea caused by C. difficile were treated with ibezapolstat 450 mg orally, twice daily for 10 days. All patients were followed for recurrence for 28± 2 days. Per protocol, after 10 patients of the projected 20 Phase 2a patients completed treatment (100% cured infection at End of Treatment), the Trial Oversight Committee assessed the safety and tolerability and made its recommendation regarding early termination of the Phase 2a study and advancement to the Ph2b segment. The Company's Scientific Advisory Board concurred with this recommendation. In the now completed Phase 2b trial segment, 32 patients with CDI were enrolled and randomized in a 1:1 ratio to either ibezapolstat 450 mg every 12 hours or vancomycin 125 mg orally every 6 hours, in each case, for 10 days and followed for 28 ± 2 days following the end of treatment for recurrence of CDI. The two treatments were identical in appearance, dosing times, and number of capsules administered to maintain the blind. The Company previously reported that the overall observed Clinical Cure rate in the combined Phase 2 trials in patients with CDI was 96% (25 out of 26 patients), based on 10 out of 10 patients (100%) in Phase 2a in the Modified Intent to Treat Population, plus 15 out of 16 (94%) patients in Phase 2b in the Per Protocol Population, who experienced Clinical Cure during treatment with ibezapolstat. Ibezapolstat was well-tolerated, with three patients each experiencing one mild adverse event assessed by the blinded investigator to be drug-related. All three events were gastrointestinal in nature and resolved without treatment. There were no drug-related treatment withdrawals or no drug-related serious adverse events, or other safety findings of concern. In the Phase 2b vancomycin control arm, 14 out of 14 patients experienced Clinical Cure. The Company is confident that based on the pooled Phase 2 ibezapolstat Clinical Cure rate of 96% and the historical vancomycin cure rate of approximately 81% (Vancocin® Prescribing Information, January 2021), we will demonstrate non-inferiority of ibezapolstat to vancomycin in Phase 3 trials in accordance with the applicable FDA Guidance for Industry (October 2022). The Phase 2b clinical trial segment was discontinued due to success. The Company made this decision in consultation with its medical and scientific advisors and statisticians based on observed aggregate blinded data and other factors, including the cost to maintain clinical trial sites and slow enrollment due to COVID-19 and its aftermath. The Company had determined that the trial performed as anticipated for both treatments, ibezapolstat and the control antibiotic vancomycin (a standard of care to treat patients with CDI), with high rates of clinical cure observed across the trial. The Phase 2b trial was originally designed to be a non-inferiority (NI) trial and later amended to include an interim efficacy analysis with review by an Independent Data Monitoring Committee (IDMC). The decision to end the trial early based on blinded clinical observations obviated the need for an interim analysis, IDMC review, and NI assessment. The Company determined, in consultation with its clinical and statistical experts, that presenting clinical cure rates for the primary efficacy endpoint is the most appropriate representation for the clinical activity of ibezapolstat in treating CDI. In the Phase 2 clinical trial, the Company will also evaluate pharmacokinetics (PK) and microbiome changes and test for anti-recurrence microbiome properties, including the change from baseline in alpha diversity and bacterial abundance, especially overgrowth of healthy gut microbiota Actinobacteria and Firmicute phylum species during and after therapy. Phase 2a data demonstrated complete eradication of colonic C. difficile by day three of treatment with ibezapolstat as well as the observed overgrowth of healthy gut microbiota, Actinobacteria and Firmicute phyla species, during and after therapy. Very importantly, emerging data show an increased concentration of secondary bile acids during and following ibezapolstat therapy which is known to correlate with colonization resistance against C. difficile. A decrease in primary bile acids and the favorable increase in the ratio of secondary-to-primary bile acids suggest that ibezapolstat may reduce the likelihood of CDI recurrence when compared to vancomycin. The company also recently reported positive extended clinical cure (ECC) data for ibezapolstat (IBZ), its lead antibiotic candidate, from the Company's recently completed Phase 2b clinical trial in patients with CDI. This exploratory endpoint showed that 12 patients who agreed to be followed up to three months following Clinical Cure of their infection, 5 of 5 IBZ patients experienced no recurrence of infection. In the vancomycin control arm of the trial, 7 of 7 patients experienced no recurrence of infection. ECC success is defined as a clinical cure at the TOC visit (i.e., at least 48 hours post EOT) and no recurrence of CDI within the 56 ± 2 days post EOT (ECC56) and 84 ± 2 days post EOT (ECC84) in patients who consented to extended observation. In the Phase 2b trial, 100% (5 of 5) of ibezapolstat-treated patients who agreed to observation for up to three months following Clinical Cure of CDI experienced no recurrence of infection. About Ibezapolstat Ibezapolstat is the Company's lead antibiotic candidate planning to advance to international Phase 3 clinical trials to treat patients with C. difficile Infection (CDI). Ibezapolstat is a novel, orally administered antibiotic being developed as a Gram-Positive Selective Spectrum (GPSS®) antibacterial. It is the first of a new class of DNA polymerase IIIC inhibitors under development by Acurx to treat bacterial infections. Ibezapolstat's unique spectrum of activity, which includes C. difficile but spares other Firmicutes and the important Actinobacteria phyla, appears to contribute to the maintenance of a healthy gut microbiome. In June 2018, ibezapolstat was designated by the U.S. Food and Drug Administration (FDA) as a Qualified Infectious Disease Product (QIDP) for the treatment of patients with CDI and will be eligible to benefit from the incentives for the development of new antibiotics established under the Generating New Antibiotic Incentives Now (GAIN) Act. In January 2019, FDA granted "Fast Track" designation to ibezapolstat for the treatment of patients with CDI. The CDC has designated C. difficile as an urgent threat highlighting the need for new antibiotics to treat CDI. About Clostridioides difficile Infection (CDI). According to the 2017 Update (published February 2018) of the Clinical Practice Guidelines for C. difficile Infection by the Infectious Diseases Society of America (IDSA) and Society or Healthcare Epidemiology of America (SHEA), CDI remains a significant medical problem in hospitals, in long-term care facilities and in the community. C. difficile is one of the most common causes of healthcare-associated infections in U.S. hospitals (Lessa, et al, 2015, New England Journal of Medicine). Recent estimates suggest C. difficile approaches 500,000 infections annually in the U.S. and is associated with approximately 20,000 deaths annually. (Guh, 2020, New England Journal of Medicine). Based on internal estimates, the recurrence rate for the antibiotics currently used to treat CDI is between 20% and 40% among approximately 150,000 patients treated. We believe the annual incidence of CDI in the U.S. approaches 600,000 infections and a mortality rate of approximately 9.3%. About the Microbiome in C. difficile Infection (CDI) and Bile Acid Metabolism C. difficile can be a normal component of the healthy gut microbiome, but when the microbiome is thrown out of balance, the C. difficile can thrive and cause an infection. After colonization with C. difficile, the organism produces and releases the main virulence factors, the two large clostridial toxins A (TcdA) and B (TcdB). (Kachrimanidou, Microorganisms 2020, 8, 200; doi:10.3390/microorganisms8020200.) TcdA and TcdB are exotoxins that bind to human intestinal epithelial cells and are responsible for inflammation, fluid and mucous secretion, as well as damage to the intestinal mucosa. Bile acids perform many functional roles in the GI tract, with one of the most important being maintenance of a healthy microbiome by inhibiting C. difficile growth. Primary bile acids, which are secreted by the liver into the intestines, promote germination of C. difficile spores and thereby increase the risk of recurrent CDI after successful treatment of an initial episode. On the other hand, secondary bile acids, which are produced by normal gut microbiota through metabolism of primary bile acids, do not induce C. difficile sporulation and therefore protect against recurrent disease. Since ibezapolstat treatment leads to minimal disruption of the gut microbiome, bacterial production of secondary bile acids continues which may contribute to an anti-recurrence effect. Beneficial effects of bile acids include a decrease in primary bile acids and an increase in secondary bile acids in patients with CDI, which was observed in the Company's Ph2a trial results and previously reported (CID, 2022). About Acurx Pharmaceuticals, Inc. Acurx Pharmaceuticals is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. The Company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS®) that blocks the active site of the Gram+ specific bacterial enzyme DNA polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its R&D pipeline includes antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE) and drug-resistant Streptococcus pneumoniae (DRSP). To learn more about Acurx Pharmaceuticals and its product pipeline, please visit Forward-Looking Statements Any statements in this press release about our future expectations, plans and prospects, including statements regarding our strategy, future operations, prospects, plans and objectives, and other statements containing the words "believes," "anticipates," "plans," "expects," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: whether ibezapolstat will benefit from the QIDP designation; whether ibezapolstat will advance through the clinical trial process on a timely basis; whether the results of the clinical trials of ibezapolstat will warrant the submission of applications for marketing approval, and if so, whether ibezapolstat will receive approval from the FDA or equivalent foreign regulatory agencies where approval is sought; whether, if ibezapolstat obtains approval, it will be successfully distributed and marketed; and other risks and uncertainties described in the Company's annual report filed with the Securities and Exchange Commission on Form 10-K for the year ended December 31, 2022, and in the Company's subsequent filings with the Securities and Exchange Commission. Such forward- looking statements speak only as of the date of this press release, and Acurx disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances after the date of such statements, except as may be required by law. Investor Contact: Acurx Pharmaceuticals, Inc. David P. Luci, President & CEO Tel: 917-533 1469 Email: [email protected] SOURCE Acurx Pharmaceuticals, Inc.

NEW YORK, Sept. 26, 2022 /PRNewswire/ -- One of the key trends in the testosterone replacement therapy market is the rise in novel therapeutic approaches. Metabolic syndrome can result in testosterone deficiency. It can be treated with anti-inflammatory drugs, which are also used to treat testosterone deficiency. The advent of new therapeutic approaches is leading to frequent market changes. Vendors are focusing on developing alternative treatment options. Thus, the growing focus of vendors on therapeutic approaches is expected to lead to the entry of new products in the global testosterone replacement therapy market, which will drive market growth. Continue Reading Technavio has announced its latest market research report titled Global Testosterone Replacement Therapy Market 2022-2026 The testosterone replacement therapy market size is expected to grow by USD 402.87 million from 2021 to 2026. In addition, the growth momentum of the market will accelerate at a CAGR of 3.1% during the forecast period, according to Technavio. Get a comprehensive report summary describing the market size and forecast along with research methodology. The FREE sample report is available in PDF format The initiatives to raise awareness about hypogonadism among the population are driving the growth of the testosterone replacement therapy market. However, factors such as the availability of generics may challenge market growth. Testosterone Replacement Therapy Market: Product Landscape By product, the market has been segmented into injectables, topicals, and others. The injectables segment will be the largest contributor to market growth during the forecast period. This growth is attributed to factors such as the prevalence of testosterone deficiency. Some of the major conditions that have been identified as risk factors for testosterone deficiency include diabetes, obesity, metabolic syndrome, and dyslipidemia. Therefore, the rise in the prevalence of testosterone deficiency is expected to accelerate the growth of the global testosterone replacement therapy market during the forecast period. Testosterone Replacement Therapy Market: Geographic Landscape By geography, the market has been segmented into North America, Europe, Asia, and the Rest of the World (ROW). North America is expected to have lucrative growth during the forecast period. About 58% of the market's overall growth is expected to originate from the region. The US and Canada are the key countries for the testosterone replacement therapy market in North America. The growth of the region is attributed to factors such as the rising number of cases of hypogonadism and raising awareness about the treatment of testosterone deficiency and erectile dysfunction. Companies Covered AbbVie Inc. Acerus Pharmaceuticals Corp. Acrux Ltd. Actiza Pharmaceutical Pvt. Ltd. Antares Pharma Inc. Aytu BioPharma Inc. Bausch Health Co. Inc. Bayer AG BIOTE MEDICAL LLC Cipla Ltd. Clarus Therapeutics Inc. Eli Lilly and Co. Endo International Plc Novartis AG Pfizer Inc. Sun Pharmaceutical Industries Ltd. Teva Pharmaceutical Industries Ltd. The Simple Pharma Co. UK Ltd. Upsher Smith Laboratories LLC Viatris Inc. This report provides a full list of key vendors, their strategies, and the latest developments. Request a FREE PDF Sample Now What our reports offer Market share assessments for the regional and country-level segments Strategic recommendations for the new entrants Covers market data for 2022, 2022, until 2026 Market trends (opportunities, drivers, threats, challenges, investment opportunities, and recommendations) Strategic recommendations in key business segments based on the market estimations Competitive landscaping highlighting the key common trends Company profiling with detailed strategies, recent developments, and financials Supply chain trends recording the latest technological advancements Related Reports Sexually Transmitted Diseases (STD) Treatment Market by Service and Geography - Forecast and Analysis 2022-2026: The sexually transmitted diseases (STD) treatment market share is expected to increase by USD 13.48 billion from 2021 to 2026. Sexual Enhancement Supplements Market by Product and Geography - Forecast and Analysis 2022-2026: The sexual enhancement supplements market share is expected to increase by USD 801.29 million from 2021 to 2026. Browse Health Care Market Reports Table of Contents 1 Executive Summary 1.1 Market overview Exhibit 01: Executive Summary – Chart on Market Overview Exhibit 02: Executive Summary – Data Table on Market Overview Exhibit 03: Executive Summary – Chart on Global Market Characteristics Exhibit 04: Executive Summary – Chart on Market by Geography Exhibit 05: Executive Summary – Chart on Market Segmentation by Product Exhibit 06: Executive Summary – Chart on Incremental Growth Exhibit 07: Executive Summary – Data Table on Incremental Growth Exhibit 08: Executive Summary – Chart on Vendor Market Positioning 2 Market Landscape 2.1 Market ecosystem Exhibit 09: Parent market Exhibit 10: Market Characteristics 3 Market Sizing 3.1 Market definition Exhibit 11: Offerings of vendors included in the market definition 3.2 Market segment analysis Exhibit 12: Market segments 3.3 Market size 2021 3.4 Market outlook: Forecast for 2021-2026 Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million) Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million) Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%) Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%) 4 Five Forces Analysis 4.1 Five forces summary Exhibit 17: Five forces analysis - Comparison between 2021 and 2026 4.2 Bargaining power of buyers Exhibit 18: Chart on Bargaining power of buyers – Impact of key factors 2021 and 2026 4.3 Bargaining power of suppliers Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026 4.4 Threat of new entrants Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026 4.5 Threat of substitutes Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026 4.6 Threat of rivalry Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026 4.7 Market condition Exhibit 23: Chart on Market condition - Five forces 2021 and 2026 5 Market Segmentation by Product 5.1 Market segments Exhibit 24: Chart on Product - Market share 2021-2026 (%) Exhibit 25: Data Table on Product - Market share 2021-2026 (%) 5.2 Comparison by Product Exhibit 26: Chart on Comparison by Product Exhibit 27: Data Table on Comparison by Product 5.3 Injectables - Market size and forecast 2021-2026 Exhibit 28: Chart on Injectables - Market size and forecast 2021-2026 ($ million) Exhibit 29: Data Table on Injectables - Market size and forecast 2021-2026 ($ million) Exhibit 30: Chart on Injectables - Year-over-year growth 2021-2026 (%) Exhibit 31: Data Table on Injectables - Year-over-year growth 2021-2026 (%) 5.4 Topicals - Market size and forecast 2021-2026 Exhibit 32: Chart on Topicals - Market size and forecast 2021-2026 ($ million) Exhibit 33: Data Table on Topicals - Market size and forecast 2021-2026 ($ million) Exhibit 34: Chart on Topicals - Year-over-year growth 2021-2026 (%) Exhibit 35: Data Table on Topicals - Year-over-year growth 2021-2026 (%) 5.5 Others - Market size and forecast 2021-2026 Exhibit 36: Chart on Others - Market size and forecast 2021-2026 ($ million) Exhibit 37: Data Table on Others - Market size and forecast 2021-2026 ($ million) Exhibit 38: Chart on Others - Year-over-year growth 2021-2026 (%) Exhibit 39: Data Table on Others - Year-over-year growth 2021-2026 (%) 5.6 Market opportunity by Product Exhibit 40: Market opportunity by Product ($ million) 6 Customer Landscape 6.1 Customer landscape overview Exhibit 41: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria 7 Geographic Landscape 7.1 Geographic segmentation Exhibit 42: Chart on Market share by geography 2021-2026 (%) Exhibit 43: Data Table on Market share by geography 2021-2026 (%) 7.2 Geographic comparison Exhibit 44: Chart on Geographic comparison Exhibit 45: Data Table on Geographic comparison 7.3 North America - Market size and forecast 2021-2026 Exhibit 46: Chart on North America - Market size and forecast 2021-2026 ($ million) Exhibit 47: Data Table on North America - Market size and forecast 2021-2026 ($ million) Exhibit 48: Chart on North America - Year-over-year growth 2021-2026 (%) Exhibit 49: Data Table on North America - Year-over-year growth 2021-2026 (%) 7.4 Europe - Market size and forecast 2021-2026 Exhibit 50: Chart on Europe - Market size and forecast 2021-2026 ($ million) Exhibit 51: Data Table on Europe - Market size and forecast 2021-2026 ($ million) Exhibit 52: Chart on Europe - Year-over-year growth 2021-2026 (%) Exhibit 53: Data Table on Europe - Year-over-year growth 2021-2026 (%) 7.5 Asia - Market size and forecast 2021-2026 Exhibit 54: Chart on Asia - Market size and forecast 2021-2026 ($ million) Exhibit 55: Data Table on Asia - Market size and forecast 2021-2026 ($ million) Exhibit 56: Chart on Asia - Year-over-year growth 2021-2026 (%) Exhibit 57: Data Table on Asia - Year-over-year growth 2021-2026 (%) 7.6 Rest of World (ROW) - Market size and forecast 2021-2026 Exhibit 58: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million) Exhibit 59: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million) Exhibit 60: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%) Exhibit 61: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%) 7.7 US - Market size and forecast 2021-2026 Exhibit 62: Chart on US - Market size and forecast 2021-2026 ($ million) Exhibit 63: Data Table on US - Market size and forecast 2021-2026 ($ million) Exhibit 64: Chart on US - Year-over-year growth 2021-2026 (%) Exhibit 65: Data Table on US - Year-over-year growth 2021-2026 (%) 7.8 Canada - Market size and forecast 2021-2026 Exhibit 66: Chart on Canada - Market size and forecast 2021-2026 ($ million) Exhibit 67: Data Table on Canada - Market size and forecast 2021-2026 ($ million) Exhibit 68: Chart on Canada - Year-over-year growth 2021-2026 (%) Exhibit 69: Data Table on Canada - Year-over-year growth 2021-2026 (%) 7.9 Germany - Market size and forecast 2021-2026 Exhibit 70: Chart on Germany - Market size and forecast 2021-2026 ($ million) Exhibit 71: Data Table on Germany - Market size and forecast 2021-2026 ($ million) Exhibit 72: Chart on Germany - Year-over-year growth 2021-2026 (%) Exhibit 73: Data Table on Germany - Year-over-year growth 2021-2026 (%) 7.10 UK - Market size and forecast 2021-2026 Exhibit 74: Chart on UK - Market size and forecast 2021-2026 ($ million) Exhibit 75: Data Table on UK - Market size and forecast 2021-2026 ($ million) Exhibit 76: Chart on UK - Year-over-year growth 2021-2026 (%) Exhibit 77: Data Table on UK - Year-over-year growth 2021-2026 (%) 7.11 China - Market size and forecast 2021-2026 Exhibit 78: Chart on China - Market size and forecast 2021-2026 ($ million) Exhibit 79: Data Table on China - Market size and forecast 2021-2026 ($ million) Exhibit 80: Chart on China - Year-over-year growth 2021-2026 (%) Exhibit 81: Data Table on China - Year-over-year growth 2021-2026 (%) 7.12 Market opportunity by geography Exhibit 82: Market opportunity by geography ($ million) 8 Drivers, Challenges, and Trends 8.1 Market drivers 8.2 Market challenges 8.3 Impact of drivers and challenges Exhibit 83: Impact of drivers and challenges in 2021 and 2026 8.4 Market trends 9 Vendor Landscape 9.1 Overview 9.2 Vendor landscape Exhibit 84: Overview on Criticality of inputs and Factors of differentiation 9.3 Landscape disruption Exhibit 85: Overview on factors of disruption 9.4 Industry risks Exhibit 86: Impact of key risks on business 10 Vendor Analysis 10.1 Vendors covered Exhibit 87: Vendors covered 10.2 Market positioning of vendors Exhibit 88: Matrix on vendor position and classification 10.3 AbbVie Inc. Exhibit 89: AbbVie Inc. - Overview Exhibit 90: AbbVie Inc. - Product / Service Exhibit 91: AbbVie Inc. - Key offerings 10.4 Acerus Pharmaceuticals Corp. Exhibit 92: Acerus Pharmaceuticals Corp. - Overview Exhibit 93: Acerus Pharmaceuticals Corp. - Product / Service Exhibit 94: Acerus Pharmaceuticals Corp. - Key offerings 10.5 Antares Pharma Inc. Exhibit 95: Antares Pharma Inc. - Overview Exhibit 96: Antares Pharma Inc. - Product / Service Exhibit 97: Antares Pharma Inc. - Key news Exhibit 98: Antares Pharma Inc. - Key offerings 10.6 Bayer AG Exhibit 99: Bayer AG - Overview Exhibit 100: Bayer AG - Business segments Exhibit 101: Bayer AG - Key offerings Exhibit 102: Bayer AG - Segment focus 10.7 Clarus Therapeutics Inc. Exhibit 103: Clarus Therapeutics Inc. - Overview Exhibit 104: Clarus Therapeutics Inc. - Product / Service Exhibit 105: Clarus Therapeutics Inc. - Key offerings 10.8 Eli Lilly and Co. Exhibit 106: Eli Lilly and Co. - Overview Exhibit 107: Eli Lilly and Co. - Product / Service Exhibit 108: Eli Lilly and Co. - Key offerings 10.9 Endo International Plc Exhibit 109: Endo International Plc - Overview Exhibit 110: Endo International Plc - Business segments Exhibit 111: Endo International Plc - Key news Exhibit 112: Endo International Plc - Key offerings Exhibit 113: Endo International Plc - Segment focus 10.10 Novartis AG Exhibit 114: Novartis AG - Overview Exhibit 115: Novartis AG - Business segments Exhibit 116: Novartis AG - Key offerings Exhibit 117: Novartis AG - Segment focus 10.11 Pfizer Inc. Exhibit 118: Pfizer Inc. - Overview Exhibit 119: Pfizer Inc. - Product / Service Exhibit 120: Pfizer Inc. - Key news Exhibit 121: Pfizer Inc. - Key offerings 10.12 The Simple Pharma Co. UK Ltd. Exhibit 122: The Simple Pharma Co. UK Ltd. - Overview Exhibit 123: The Simple Pharma Co. UK Ltd. - Product / Service Exhibit 124: The Simple Pharma Co. UK Ltd. - Key offerings 11 Appendix 11.1 Scope of the report 11.2 Inclusions and exclusions checklist Exhibit 125: Inclusions checklist Exhibit 126: Exclusions checklist 11.3 Currency conversion rates for US$ Exhibit 127: Currency conversion rates for US$ 11.4 Research methodology Exhibit 128: Research methodology Exhibit 129: Validation techniques employed for market sizing Exhibit 130: Information sources 11.5 List of abbreviations Exhibit 131: List of abbreviations About Us Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contact Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email: [email protected] Website: SOURCE Technavio

New York, March 12, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Topical Drug Delivery Industry" - In addition to being a global intelligence exchange platform, MarketGlass™ is a powerful knowledge center that delivers dynamic project-focused market intelligence. Client companies will have complete insider access to the project Data stack. - Interactive peer-to-peer and enterprise-to-enterprise ideation and market intelligence exchange is facilitated via a robust, secure, and validated process. The process draws from uniquely qualified project-specific and geographically focused executives overseeing business development, marketing and sales operations. Trends & Factors - Identifying and validating local trends and factors driving each competitive marketplace. These factors include pricing variances, market trajectories, Covid-19 impact and recovery, locally active leading brands, and other parameters impacting the region in the short to medium term such as supply chain realignments. Identifying and validating local trends and factors driving each competitive marketplace. These factors include pricing variances, market trajectories, Covid-19 impact and recovery, locally active leading brands, and other parameters impacting the region in the short to medium term such as supply chain realignments. Mobile Access & App - Our mobile version of the report may be accessed via our mobile app or directly for a full mobile experience. Our mobile version of the report may be accessed via our mobile app or directly for a full mobile experience. Complimentary Updates - for one year. At least one update in 12-month period is normal and anytime there’s a significant change affecting the market dynamics. for one year. At least one update in 12-month period is normal and anytime there’s a significant change affecting the market dynamics. Bespoke Updates & Team Collaborations - Clients may build a bespoke version of our report with peers on our MarketGlass™ platform which enables multidimensional data simulations. Clients may build a bespoke version of our report with peers on our MarketGlass™ platform which enables multidimensional data simulations. Knowledge Center - clients have full-stack data access for project data they support or purchase including primary research engagement stats, companies and executives. Abstract: - Global Topical Drug Delivery Market to Reach $129.9 Billion by 2027 - Amid the COVID-19 crisis, the global market for Topical Drug Delivery estimated at US$92.4 Billion in the year 2020, is projected to reach a revised size of US$129.9 Billion by 2027, growing at a CAGR of 5% over the analysis period 2020-2027. Semi-Solid Formulations, one of the segments analyzed in the report, is projected to record a 5.1% CAGR and reach US$51.1 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Liquid Formulations segment is readjusted to a revised 4.6% CAGR for the next 7-year period. - The U.S. Market is Estimated at $27.2 Billion, While China is Forecast to Grow at 4.7% CAGR - The Topical Drug Delivery market in the U.S. is estimated at US$27.2 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$22.9 Billion by the year 2027 trailing a CAGR of 4.7% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.8% and 3.9% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.1% CAGR. - Solid Formulations Segment to Record 4.4% CAGR - In the global Solid Formulations segment, USA, Canada, Japan, China and Europe will drive the 4.4% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$14.1 Billion in the year 2020 will reach a projected size of US$19.1 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$14.9 Billion by the year 2027. Select Competitors (Total 43 Featured) - 3M Acrux Limited Bayer AG Biofarmitalia s.r.l Cipla Inc. Crescita Therapeutics Inc. Galderma S.A. GlaxoSmithKline plc Janssen Global Services, LLC Lohmann Therapie-Systeme AG Medpharm Mylan N.V. Nitto Denko Corporation Novartis AG Pharmatek Laboratories, Inc. Pocono Coated Products LLC Skinvisible Pharmaceuticals, Inc. Stiefel Laboratories, Inc. Tapemark Valeant Pharmaceuticals International, Inc. West Pharmaceutical Services, Inc. Read the full report: I. METHODOLOGY II. EXECUTIVE SUMMARY 1. MARKET OVERVIEW Influencer Market Insights World Market Trajectories Impact of Covid-19 and a Looming Global Recession Global Competitor Market Shares Topical Drug Delivery Competitor Market Share Scenario Worldwide (in %): 2020E Global Competitor Market Shares by Segment 2. FOCUS ON SELECT PLAYERS 3. MARKET TRENDS & DRIVERS 4. GLOBAL MARKET PERSPECTIVE Table 1: World Current & Future Analysis for Topical Drug Delivery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 2: World Historic Review for Topical Drug Delivery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 3: World 15-Year Perspective for Topical Drug Delivery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027 Table 4: World Current & Future Analysis for Semi-Solid Formulations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 5: World Historic Review for Semi-Solid Formulations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 6: World 15-Year Perspective for Semi-Solid Formulations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 Table 7: World Current & Future Analysis for Liquid Formulations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 8: World Historic Review for Liquid Formulations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 9: World 15-Year Perspective for Liquid Formulations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 Table 10: World Current & Future Analysis for Solid Formulations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 11: World Historic Review for Solid Formulations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 12: World 15-Year Perspective for Solid Formulations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 Table 13: World Current & Future Analysis for Transdermal Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 14: World Historic Review for Transdermal Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 15: World 15-Year Perspective for Transdermal Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 Table 16: World Current & Future Analysis for Home Care Settings by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 17: World Historic Review for Home Care Settings by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 18: World 15-Year Perspective for Home Care Settings by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 Table 19: World Current & Future Analysis for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 20: World Historic Review for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 21: World 15-Year Perspective for Hospitals & Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 Table 22: World Current & Future Analysis for Burn Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 23: World Historic Review for Burn Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 24: World 15-Year Perspective for Burn Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 Table 25: World Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 26: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 27: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 Table 28: World Current & Future Analysis for Dermal Drug Delivery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 29: World Historic Review for Dermal Drug Delivery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 30: World 15-Year Perspective for Dermal Drug Delivery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 Table 31: World Current & Future Analysis for Nasal Drug Delivery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 32: World Historic Review for Nasal Drug Delivery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 33: World 15-Year Perspective for Nasal Drug Delivery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 Table 34: World Current & Future Analysis for Ophthalmic Drug Delivery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 35: World Historic Review for Ophthalmic Drug Delivery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 36: World 15-Year Perspective for Ophthalmic Drug Delivery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 Table 37: World Current & Future Analysis for Rectal Drug Delivery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 38: World Historic Review for Rectal Drug Delivery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 39: World 15-Year Perspective for Rectal Drug Delivery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 Table 40: World Current & Future Analysis for Vaginal Drug Delivery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 41: World Historic Review for Vaginal Drug Delivery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 42: World 15-Year Perspective for Vaginal Drug Delivery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 III. MARKET ANALYSIS UNITED STATES Market Facts & Figures Market Analytics Table 43: USA Current & Future Analysis for Topical Drug Delivery by Product - Semi-Solid Formulations, Liquid Formulations, Solid Formulations and Transdermal Products - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 44: USA Historic Review for Topical Drug Delivery by Product - Semi-Solid Formulations, Liquid Formulations, Solid Formulations and Transdermal Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 45: USA 15-Year Perspective for Topical Drug Delivery by Product - Percentage Breakdown of Value Sales for Semi-Solid Formulations, Liquid Formulations, Solid Formulations and Transdermal Products for the Years 2012, 2020 & 2027 Table 46: USA Current & Future Analysis for Topical Drug Delivery by End-Use - Home Care Settings, Hospitals & Clinics, Burn Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 47: USA Historic Review for Topical Drug Delivery by End-Use - Home Care Settings, Hospitals & Clinics, Burn Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 48: USA 15-Year Perspective for Topical Drug Delivery by End-Use - Percentage Breakdown of Value Sales for Home Care Settings, Hospitals & Clinics, Burn Centers and Other End-Uses for the Years 2012, 2020 & 2027 Table 49: USA Current & Future Analysis for Topical Drug Delivery by Route Of Administration - Dermal Drug Delivery, Nasal Drug Delivery, Ophthalmic Drug Delivery, Rectal Drug Delivery and Vaginal Drug Delivery - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 50: USA Historic Review for Topical Drug Delivery by Route Of Administration - Dermal Drug Delivery, Nasal Drug Delivery, Ophthalmic Drug Delivery, Rectal Drug Delivery and Vaginal Drug Delivery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 51: USA 15-Year Perspective for Topical Drug Delivery by Route Of Administration - Percentage Breakdown of Value Sales for Dermal Drug Delivery, Nasal Drug Delivery, Ophthalmic Drug Delivery, Rectal Drug Delivery and Vaginal Drug Delivery for the Years 2012, 2020 & 2027 CANADA Table 52: Canada Current & Future Analysis for Topical Drug Delivery by Product - Semi-Solid Formulations, Liquid Formulations, Solid Formulations and Transdermal Products - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 53: Canada Historic Review for Topical Drug Delivery by Product - Semi-Solid Formulations, Liquid Formulations, Solid Formulations and Transdermal Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 54: Canada 15-Year Perspective for Topical Drug Delivery by Product - Percentage Breakdown of Value Sales for Semi-Solid Formulations, Liquid Formulations, Solid Formulations and Transdermal Products for the Years 2012, 2020 & 2027 Table 55: Canada Current & Future Analysis for Topical Drug Delivery by End-Use - Home Care Settings, Hospitals & Clinics, Burn Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 56: Canada Historic Review for Topical Drug Delivery by End-Use - Home Care Settings, Hospitals & Clinics, Burn Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 57: Canada 15-Year Perspective for Topical Drug Delivery by End-Use - Percentage Breakdown of Value Sales for Home Care Settings, Hospitals & Clinics, Burn Centers and Other End-Uses for the Years 2012, 2020 & 2027 Table 58: Canada Current & Future Analysis for Topical Drug Delivery by Route Of Administration - Dermal Drug Delivery, Nasal Drug Delivery, Ophthalmic Drug Delivery, Rectal Drug Delivery and Vaginal Drug Delivery - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 59: Canada Historic Review for Topical Drug Delivery by Route Of Administration - Dermal Drug Delivery, Nasal Drug Delivery, Ophthalmic Drug Delivery, Rectal Drug Delivery and Vaginal Drug Delivery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 60: Canada 15-Year Perspective for Topical Drug Delivery by Route Of Administration - Percentage Breakdown of Value Sales for Dermal Drug Delivery, Nasal Drug Delivery, Ophthalmic Drug Delivery, Rectal Drug Delivery and Vaginal Drug Delivery for the Years 2012, 2020 & 2027 JAPAN Table 61: Japan Current & Future Analysis for Topical Drug Delivery by Product - Semi-Solid Formulations, Liquid Formulations, Solid Formulations and Transdermal Products - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 62: Japan Historic Review for Topical Drug Delivery by Product - Semi-Solid Formulations, Liquid Formulations, Solid Formulations and Transdermal Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 63: Japan 15-Year Perspective for Topical Drug Delivery by Product - Percentage Breakdown of Value Sales for Semi-Solid Formulations, Liquid Formulations, Solid Formulations and Transdermal Products for the Years 2012, 2020 & 2027 Table 64: Japan Current & Future Analysis for Topical Drug Delivery by End-Use - Home Care Settings, Hospitals & Clinics, Burn Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 65: Japan Historic Review for Topical Drug Delivery by End-Use - Home Care Settings, Hospitals & Clinics, Burn Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 66: Japan 15-Year Perspective for Topical Drug Delivery by End-Use - Percentage Breakdown of Value Sales for Home Care Settings, Hospitals & Clinics, Burn Centers and Other End-Uses for the Years 2012, 2020 & 2027 Table 67: Japan Current & Future Analysis for Topical Drug Delivery by Route Of Administration - Dermal Drug Delivery, Nasal Drug Delivery, Ophthalmic Drug Delivery, Rectal Drug Delivery and Vaginal Drug Delivery - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 68: Japan Historic Review for Topical Drug Delivery by Route Of Administration - Dermal Drug Delivery, Nasal Drug Delivery, Ophthalmic Drug Delivery, Rectal Drug Delivery and Vaginal Drug Delivery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 69: Japan 15-Year Perspective for Topical Drug Delivery by Route Of Administration - Percentage Breakdown of Value Sales for Dermal Drug Delivery, Nasal Drug Delivery, Ophthalmic Drug Delivery, Rectal Drug Delivery and Vaginal Drug Delivery for the Years 2012, 2020 & 2027 CHINA Table 70: China Current & Future Analysis for Topical Drug Delivery by Product - Semi-Solid Formulations, Liquid Formulations, Solid Formulations and Transdermal Products - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 71: China Historic Review for Topical Drug Delivery by Product - Semi-Solid Formulations, Liquid Formulations, Solid Formulations and Transdermal Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 72: China 15-Year Perspective for Topical Drug Delivery by Product - Percentage Breakdown of Value Sales for Semi-Solid Formulations, Liquid Formulations, Solid Formulations and Transdermal Products for the Years 2012, 2020 & 2027 Table 73: China Current & Future Analysis for Topical Drug Delivery by End-Use - Home Care Settings, Hospitals & Clinics, Burn Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 74: China Historic Review for Topical Drug Delivery by End-Use - Home Care Settings, Hospitals & Clinics, Burn Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 75: China 15-Year Perspective for Topical Drug Delivery by End-Use - Percentage Breakdown of Value Sales for Home Care Settings, Hospitals & Clinics, Burn Centers and Other End-Uses for the Years 2012, 2020 & 2027 Table 76: China Current & Future Analysis for Topical Drug Delivery by Route Of Administration - Dermal Drug Delivery, Nasal Drug Delivery, Ophthalmic Drug Delivery, Rectal Drug Delivery and Vaginal Drug Delivery - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 77: China Historic Review for Topical Drug Delivery by Route Of Administration - Dermal Drug Delivery, Nasal Drug Delivery, Ophthalmic Drug Delivery, Rectal Drug Delivery and Vaginal Drug Delivery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 78: China 15-Year Perspective for Topical Drug Delivery by Route Of Administration - Percentage Breakdown of Value Sales for Dermal Drug Delivery, Nasal Drug Delivery, Ophthalmic Drug Delivery, Rectal Drug Delivery and Vaginal Drug Delivery for the Years 2012, 2020 & 2027 EUROPE Market Facts & Figures Market Analytics Table 79: Europe Current & Future Analysis for Topical Drug Delivery by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 80: Europe Historic Review for Topical Drug Delivery by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 81: Europe 15-Year Perspective for Topical Drug Delivery by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027 Table 82: Europe Current & Future Analysis for Topical Drug Delivery by Product - Semi-Solid Formulations, Liquid Formulations, Solid Formulations and Transdermal Products - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 83: Europe Historic Review for Topical Drug Delivery by Product - Semi-Solid Formulations, Liquid Formulations, Solid Formulations and Transdermal Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 84: Europe 15-Year Perspective for Topical Drug Delivery by Product - Percentage Breakdown of Value Sales for Semi-Solid Formulations, Liquid Formulations, Solid Formulations and Transdermal Products for the Years 2012, 2020 & 2027 Table 85: Europe Current & Future Analysis for Topical Drug Delivery by End-Use - Home Care Settings, Hospitals & Clinics, Burn Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 86: Europe Historic Review for Topical Drug Delivery by End-Use - Home Care Settings, Hospitals & Clinics, Burn Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 87: Europe 15-Year Perspective for Topical Drug Delivery by End-Use - Percentage Breakdown of Value Sales for Home Care Settings, Hospitals & Clinics, Burn Centers and Other End-Uses for the Years 2012, 2020 & 2027 Table 88: Europe Current & Future Analysis for Topical Drug Delivery by Route Of Administration - Dermal Drug Delivery, Nasal Drug Delivery, Ophthalmic Drug Delivery, Rectal Drug Delivery and Vaginal Drug Delivery - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 89: Europe Historic Review for Topical Drug Delivery by Route Of Administration - Dermal Drug Delivery, Nasal Drug Delivery, Ophthalmic Drug Delivery, Rectal Drug Delivery and Vaginal Drug Delivery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 90: Europe 15-Year Perspective for Topical Drug Delivery by Route Of Administration - Percentage Breakdown of Value Sales for Dermal Drug Delivery, Nasal Drug Delivery, Ophthalmic Drug Delivery, Rectal Drug Delivery and Vaginal Drug Delivery for the Years 2012, 2020 & 2027 FRANCE Table 91: France Current & Future Analysis for Topical Drug Delivery by Product - Semi-Solid Formulations, Liquid Formulations, Solid Formulations and Transdermal Products - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 92: France Historic Review for Topical Drug Delivery by Product - Semi-Solid Formulations, Liquid Formulations, Solid Formulations and Transdermal Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 93: France 15-Year Perspective for Topical Drug Delivery by Product - Percentage Breakdown of Value Sales for Semi-Solid Formulations, Liquid Formulations, Solid Formulations and Transdermal Products for the Years 2012, 2020 & 2027 Table 94: France Current & Future Analysis for Topical Drug Delivery by End-Use - Home Care Settings, Hospitals & Clinics, Burn Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 95: France Historic Review for Topical Drug Delivery by End-Use - Home Care Settings, Hospitals & Clinics, Burn Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 96: France 15-Year Perspective for Topical Drug Delivery by End-Use - Percentage Breakdown of Value Sales for Home Care Settings, Hospitals & Clinics, Burn Centers and Other End-Uses for the Years 2012, 2020 & 2027 Table 97: France Current & Future Analysis for Topical Drug Delivery by Route Of Administration - Dermal Drug Delivery, Nasal Drug Delivery, Ophthalmic Drug Delivery, Rectal Drug Delivery and Vaginal Drug Delivery - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 98: France Historic Review for Topical Drug Delivery by Route Of Administration - Dermal Drug Delivery, Nasal Drug Delivery, Ophthalmic Drug Delivery, Rectal Drug Delivery and Vaginal Drug Delivery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 99: France 15-Year Perspective for Topical Drug Delivery by Route Of Administration - Percentage Breakdown of Value Sales for Dermal Drug Delivery, Nasal Drug Delivery, Ophthalmic Drug Delivery, Rectal Drug Delivery and Vaginal Drug Delivery for the Years 2012, 2020 & 2027 GERMANY Table 100: Germany Current & Future Analysis for Topical Drug Delivery by Product - Semi-Solid Formulations, Liquid Formulations, Solid Formulations and Transdermal Products - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 101: Germany Historic Review for Topical Drug Delivery by Product - Semi-Solid Formulations, Liquid Formulations, Solid Formulations and Transdermal Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 102: Germany 15-Year Perspective for Topical Drug Delivery by Product - Percentage Breakdown of Value Sales for Semi-Solid Formulations, Liquid Formulations, Solid Formulations and Transdermal Products for the Years 2012, 2020 & 2027 Table 103: Germany Current & Future Analysis for Topical Drug Delivery by End-Use - Home Care Settings, Hospitals & Clinics, Burn Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 104: Germany Historic Review for Topical Drug Delivery by End-Use - Home Care Settings, Hospitals & Clinics, Burn Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 105: Germany 15-Year Perspective for Topical Drug Delivery by End-Use - Percentage Breakdown of Value Sales for Home Care Settings, Hospitals & Clinics, Burn Centers and Other End-Uses for the Years 2012, 2020 & 2027 Table 106: Germany Current & Future Analysis for Topical Drug Delivery by Route Of Administration - Dermal Drug Delivery, Nasal Drug Delivery, Ophthalmic Drug Delivery, Rectal Drug Delivery and Vaginal Drug Delivery - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 107: Germany Historic Review for Topical Drug Delivery by Route Of Administration - Dermal Drug Delivery, Nasal Drug Delivery, Ophthalmic Drug Delivery, Rectal Drug Delivery and Vaginal Drug Delivery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 108: Germany 15-Year Perspective for Topical Drug Delivery by Route Of Administration - Percentage Breakdown of Value Sales for Dermal Drug Delivery, Nasal Drug Delivery, Ophthalmic Drug Delivery, Rectal Drug Delivery and Vaginal Drug Delivery for the Years 2012, 2020 & 2027 ITALY Table 109: Italy Current & Future Analysis for Topical Drug Delivery by Product - Semi-Solid Formulations, Liquid Formulations, Solid Formulations and Transdermal Products - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 110: Italy Historic Review for Topical Drug Delivery by Product - Semi-Solid Formulations, Liquid Formulations, Solid Formulations and Transdermal Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 111: Italy 15-Year Perspective for Topical Drug Delivery by Product - Percentage Breakdown of Value Sales for Semi-Solid Formulations, Liquid Formulations, Solid Formulations and Transdermal Products for the Years 2012, 2020 & 2027 Table 112: Italy Current & Future Analysis for Topical Drug Delivery by End-Use - Home Care Settings, Hospitals & Clinics, Burn Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 113: Italy Historic Review for Topical Drug Delivery by End-Use - Home Care Settings, Hospitals & Clinics, Burn Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 114: Italy 15-Year Perspective for Topical Drug Delivery by End-Use - Percentage Breakdown of Value Sales for Home Care Settings, Hospitals & Clinics, Burn Centers and Other End-Uses for the Years 2012, 2020 & 2027 Table 115: Italy Current & Future Analysis for Topical Drug Delivery by Route Of Administration - Dermal Drug Delivery, Nasal Drug Delivery, Ophthalmic Drug Delivery, Rectal Drug Delivery and Vaginal Drug Delivery - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 116: Italy Historic Review for Topical Drug Delivery by Route Of Administration - Dermal Drug Delivery, Nasal Drug Delivery, Ophthalmic Drug Delivery, Rectal Drug Delivery and Vaginal Drug Delivery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 117: Italy 15-Year Perspective for Topical Drug Delivery by Route Of Administration - Percentage Breakdown of Value Sales for Dermal Drug Delivery, Nasal Drug Delivery, Ophthalmic Drug Delivery, Rectal Drug Delivery and Vaginal Drug Delivery for the Years 2012, 2020 & 2027 UNITED KINGDOM Table 118: UK Current & Future Analysis for Topical Drug Delivery by Product - Semi-Solid Formulations, Liquid Formulations, Solid Formulations and Transdermal Products - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 119: UK Historic Review for Topical Drug Delivery by Product - Semi-Solid Formulations, Liquid Formulations, Solid Formulations and Transdermal Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 120: UK 15-Year Perspective for Topical Drug Delivery by Product - Percentage Breakdown of Value Sales for Semi-Solid Formulations, Liquid Formulations, Solid Formulations and Transdermal Products for the Years 2012, 2020 & 2027 Table 121: UK Current & Future Analysis for Topical Drug Delivery by End-Use - Home Care Settings, Hospitals & Clinics, Burn Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 122: UK Historic Review for Topical Drug Delivery by Please contact our Customer Support Center to get the complete Table of Contents Read the full report: About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________ Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001